Last reviewed · How we verify

Almirall — Portfolio Competitive Intelligence Brief

Almirall (ALM.MC) pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ALM.MC (Bolsa de Madrid) 3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Klisyri TIRBANIBULIN marketed Microtubule Inhibitor [EPC] Tyrosine-protein kinase Lyn Other 2020-01-01
Altabax RETAPAMULIN marketed Pleuromutilin Antibacterial Infectious Disease 2007-01-01
Aczone DAPSONE marketed Sulfone [EPC] 5-hydroxytryptamine receptor 6 Immunology 1979-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Almirall, S.A. · 1 shared drug class
  3. Hong Kong · 1 shared drug class
  4. Pfizer · 1 shared drug class
  5. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Almirall:

Cite this brief

Drug Landscape (2026). Almirall — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/almirall. Accessed 2026-06-10.

Related